MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Drug Development
Drug Development
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Drug Development
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Drug Development
Drug Development

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Drug Development
Journal Article

Drug Development

2025
Request Book From Autostore and Choose the Collection Method
Overview
The comparative neuroprotective effects of different hypoglycemic drugs have not been characterized in randomized controlled trials. Here, we investigated the effects of dapagliflozin, liraglutide, or acarbose treatment on the directed functional connectivity of primary olfactory cortex (POC) circuit and local activation under odor stimulation in patients with type 2 diabetes (T2D). In the 16-week randomized parallel-group open-label trial, 36 patients with T2D, inadequately controlled with metformin, were randomized 1:1:1 to receive dapagliflozin, liraglutide or acarbose. Simultaneously, 36 normal controls were recruited. Olfactory task functional MRI and a battery of olfactory and cognitive tests were conducted in all subjects and postintervention. Generalized psychophysiological interaction analysis was used to identify directed functional connectivity of POC circuit under odor stimulation. The 16-week treatment with dapagliflozin restored odor-induced functional integration of POC-sensorimotor cortex-middle temporal cortex circuit with Gaussian random field correction, but liraglutide and acarbose did not, and dapagliflozin tended to improve attention (P = 0.071). Liraglutide enhanced odor-induced activation in the left hippocampus, but dapagliflozin and acarbose did not. The decreased odor-induced directed functional connectivity was associated with improvements in lipid levels and changes in olfactory threshold, executive function, and memory performance (all P < 0.05). These results suggest that dapagliflozin and liraglutide have unique neuroprotective effects, respectively. Liraglutide may act on the activation of local olfactory-related regions, while dapagliflozin acts on the functional integration of neural circuits. These findings highlight the importance of targeting both metabolic and neural pathways in the management of T2D-related cognitive decline.